Acute Respiratory Distress Syndrome
Conditions
Brief summary
To evaluate the safety, tolerability, PK, PD, and clinical activity of Itolizumab in subjects with acute respiratory distress syndrome (ARDS) caused by Infectious Pneumonia.
Detailed description
The study will enroll approximately 38 subjects in two parts: Part 1 is an open label 3+3 single dose escalation phase. 9-24 patients with ARDS caused by infectious pneumonia across 3 dose cohorts. Part 2 is a randomized phase and will enroll approximately 14 additional participants, randomized in a 1:1 ratio to one of the 2 doses based on efficacy data obtained from Part 1. All participants in this study will receive Itolizumab intravenously for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
Interventions
DRUGItolizumab
Patients to be treated with Itolizumab.
Sponsors
Biotech Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female subject aged 18-75 years old (inclusive) 2. Clinical diagnosis with infectious pneumonia as determined by the investigator 3. Subject who havd received anti-infective treatment according to clinical practice. 4. Diagnosis with ARDS according to the following criteria: (i) Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules; (ii) respiratory failure not fully explained by cardiac failure or fluid overload; (iii) Oxygenation (PaO2/FiO2) ≤300. 5. ARDS diagnosed within 48 hours before administration, and fullfil the criteria of ARDS before administration 6. Fullfill at least 2 of the following 4 criteria: ① elevated hs-CRP (\>6 ULN); ② elevated IL-6 (\>3 ULN); ③ high serum ferritin (\>500µg/L at any one time or more than 2-fold increase within 48 hours of onset); ④ high D-dimer (\>3 ULN). 7. Negative result of serum HCG within 72 hours before enrollment for female with potential fertility 8. Participant or his/her legal representive (when the participant is not capable of giving consent) is able to understand and comply with the planned procedure as required by the protocol, and sign a written informed consent form (ICF)
Exclusion criteria
1. ARDS caused by non-infectious pneumonia (e.g., burns, drowning, poisoning, etc.) 2. Subject who has cardiogenic pulmonary edema, and it is the main cause of respiratory failure 3. Subject who is at high risk of death within 24 hours regardless of the treatment measures given as determined by the investigator 4. Subject who is receiving extracorporeal membrane pulmonary oxygenation (ECMO) therapy at the time of screening. 5. Subject who had received mechanical ventilation for more than 72 hours prior to administration. 6. Subject with active tumors (other than carcinoma in situ or basal cell carcinoma) that requiring treatment. 7. Any of the following chronic organ damage or immunosuppression: 1. Cardiac: cardiac arrest within 7 days prior to screening; New York Heart Association cardiac function class IV at screening; 2. Pulmonary: oxygen therapy or ventilator-dependent therapy for more than 1 month cumulatively within 6 months prior to screening; pulmonary embolism within 4 weeks prior to screening; pulmonary hypertension, end-stage lung disease, or interstitial lung disease requiring glucocorticoid therapy at screening; 3. Renal: serum creatinine \> 1.5 ULN or creatinine clearance \< 30 mL/min at screening (Cockcroft-Gault formula, see study protocol annex 5 for details) or on long-term dialysis treatment; 4. Liver: liver function classification of Child-Pugh grade C at screening; 5. Immunosuppression status: with lymphoma, leukemia or acquired immunodeficiency; having received antitumor chemotherapy in the last 3 months, or being treated with immunosuppression for organ transplantation or immune disorders; having had allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation. 8. Subject who had vaccination within 28 days prior to administration, or plan to get the vaccine during the study period 9. Any of the following abnormalities at screening 1. Hepatitis B-related tests: ① positive for hepatitis B surface antigen (HBsAg); ② positive for hepatitis B core antibody (HBcAb); ③ positive for hepatitis B surface antibody (HBsAb) and no history of hepatitis B vaccination; ④ positive for hepatitis B e antigen or hepatitis B e antibody; 2. Positive hepatitis C virus antibody (HCV-Ab); 3. Positive acquired immunodeficiency syndrome antibody (HIV-Ab). 10. Subject who has a medical history of tuberculosis or those who deny a history of tuberculosis but has a positive gamma-interferon release test at screening. 11. Absolute lymphocyte count \< 0.2×109/L at screening 12. Suspected allergic to the investigational drug or any of its excipients 13. Currently pregnant, breastfeeding,or planning to become pregnant or not using reliable method to avoid pregnancy during study and within 3 months after the last study treatment 14. Subject who had participated in other clinical studies (other than those not receiving interventions, such as observational study or questionnaires survey) within 3 months prior to screening, or who are participating in other experimental treatments. 15. As determined by the investigator, any medical, psychiatric, or other condition or circumstance that is likely to negatively affect the reliability of the study data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events | Study Day 58 | Number of subjects with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum serum concentration of Itolizumab, Cmax | Study Day 30 | Maximum serum concentration of Itolizumab |
| Minimum serum concentration of Itolizumab, Cmin | Study Day 30 | Minimum serum concentration of Itolizumab |
| Time to maximum serum concentration of Itolizumab, Tmax | Study Day 30 | Time to maximum serum concentration of Itolizumab |
| Total Itolizumab exposure across time, AUC0-t | Study Day 30 | Total Itolizumab exposure across time |
| Half life of Itolizumab, t1/2 | Study Day 30 | Half life of Itolizumab |
| Inflammatory Markers,IL-6 | Study Day 30 | IL-6 |
| Inflammatory Markers,TNF-α | Study Day 30 | TNF-α |
| Inflammatory Markers, hs-CRP | Study Day 30 | hs-CRP |
| Inflammatory Markers,Serum ferritin | Study Day 30 | Serum ferritin |
| Inflammatory Markers,D-dimer | Study Day 30 | D-dimer |
| CD6 receptor expression levels | Study Day 30 | Mean change of CD6 receptor expression levels in relative to baseline |
| T cell subsets | Study Day 30 | Mean change of different T cell subsets in relative to baseline |
| The proportion of patients with stable or improved Lung Function | Study Day 30 | Defined as patients with stable or improved PaO2 without increasing FiO2 in relative to baseline |
| Mean change from baseline in Murray Score | Study Day 30 | Mean change of Murray Score in relative to baseline，The higher score means the worse outcome |
| Mean change from baseline in SOFA score | Study Day 30 | Mean change of SOFA（Sequential Organ Failure Assessment） score in relative to baseline，The higher score means the worse outcome |
| Mechanical ventilation-free days | Study Day 30 | Duration of non-Mechanical ventilation |
| Oxygen therapy-free days | Study Day 30 | Duration of non-Oxygen therapy |
| Duration of ICU stay | Study Day 30 | ICU stay days |
| Mortality rate | Study Day 15, 30 | Defined as the proportion of patients who met fatal outcome event by Day 15 and 30 |
| Clinical status assessed using a 7-category ordinal scale | Study Day 30 | Clinical status assessed using a 7-category ordinal scale |
| Incidence of ADA | Study Day 30 | Defined as the precentage of subjects presenting anti-drug antibody |
Contacts
Primary ContactDANDAN Gao
Outcome results
None listed